financetom
Business
financetom
/
Business
/
Accenture Unusual Options Activity
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Accenture Unusual Options Activity
Jul 26, 2024 12:29 PM

Investors with significant funds have taken a bearish position in Accenture ( ACN ) , a development that retail traders should be aware of.

This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga. The exact nature of these investors remains a mystery, but such a major move in ACN usually indicates foreknowledge of upcoming events.

Today, Benzinga's options scanner identified 14 options transactions for Accenture ( ACN ). This is an unusual occurrence. The sentiment among these large-scale traders is mixed, with 28% being bullish and 50% bearish. Of all the options we discovered, 13 are puts, valued at $762,603, and there was a single call, worth $35,460.

Projected Price Targets

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $200.0 and $335.0 for Accenture ( ACN ), spanning the last three months.

Analyzing Volume & Open Interest

Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Accenture's ( ACN ) options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Accenture's ( ACN ) whale trades within a strike price range from $200.0 to $335.0 in the last 30 days.

Accenture Option Activity Analysis: Last 30 Days

Noteworthy Options Activity:

Symbol PUT/CALL Trade Type Sentiment Exp. Date Ask Bid Price Strike Price Total Trade Price Open Interest Volume
ACN PUT SWEEP BULLISH 10/18/24 $17.2 $17.1 $17.13 $335.00 $169.3K 70 104
ACN PUT SWEEP BULLISH 10/18/24 $17.6 $17.5 $17.52 $335.00 $91.0K 70 358
ACN PUT SWEEP BEARISH 10/18/24 $17.9 $17.7 $17.78 $335.00 $67.5K 70 613
ACN PUT SWEEP BEARISH 10/18/24 $17.8 $17.7 $17.78 $335.00 $56.9K 70 483
ACN PUT SWEEP BULLISH 10/18/24 $17.6 $17.5 $17.52 $335.00 $56.0K 70 376

About Accenture

Accenture ( ACN ) is a leading global IT-services firm that provides consulting, strategy, and technology and operational services. These services run the gamut from aiding enterprises with digital transformation to procurement services to software system integration. The company provides its IT offerings to a variety of sectors, including communications, media and technology, financial services, health and public services, consumer products, and resources. Accenture ( ACN ) employs just under 500,000 people throughout 200 cities in 51 countries.

Following our analysis of the options activities associated with Accenture ( ACN ), we pivot to a closer look at the company's own performance.

Accenture's Current Market Status

Trading volume stands at 1,495,277, with ACN's price down by -0.67%, positioned at $327.9.

RSI indicators show the stock to be may be approaching overbought.

Earnings announcement expected in 62 days.

What Analysts Are Saying About Accenture

Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $400.0.

In a positive move, an analyst from UBS has upgraded their rating to Buy and adjusted the price target to $400.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Accenture ( ACN ) options trades with real-time alerts from Benzinga Pro.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Shake Shack Stock Gains After Q3 Earnings Beat Amid Strong Sales Growth, Strategic Expansion
Shake Shack Stock Gains After Q3 Earnings Beat Amid Strong Sales Growth, Strategic Expansion
Nov 3, 2024
Shake Shack, Inc. ( SHAK ) shares are trading higher after the company reported better-than-expected third-quarter financial results. Shake Shack ( SHAK ) reported adjusted earnings per share of 25 cents, beating the street view of 20 cents. Quarterly revenues of $316.9 million (+14.7%) marginally outpaced the analyst consensus estimate of $316.13 million. Sales included $304.9 million from Shack sales...
Philips, Aspen Dental Launch Partnership Focusing on Sonicare Products
Philips, Aspen Dental Launch Partnership Focusing on Sonicare Products
Nov 3, 2024
11:18 AM EDT, 10/30/2024 (MT Newswires) -- Royal Philips (PHG) said Wednesday it is launching a partnership with Aspen Dental to bring its Sonicare toothbrush and related products to Aspen Dental's national network of more than 1,100 locations. Under the partnership, Aspen Dental's clinicians will be able offer Sonicare solutions in office, Philips said. Financial details weren't provided. Price: 26.14,...
Lexeo Therapeutics Sees 'Positive' Interim Results for LX1001 to Treat APOE4-Linked Alzheimer's Disease
Lexeo Therapeutics Sees 'Positive' Interim Results for LX1001 to Treat APOE4-Linked Alzheimer's Disease
Nov 3, 2024
11:04 AM EDT, 10/30/2024 (MT Newswires) -- Lexeo Therapeutics ( LXEO ) said Wednesday it has seen positive interim data from a phase 1/2 trial of LX1001 to treat APOE4-associated Alzheimer's disease. Treatment with the gene therapy candidate resulted in dose-dependent increases in APOE2 protein expression and improvements in AD-associated tau biomarkers, measures which have been closely correlated with cognitive...
Tharimmune Shares Climb on Positive Feedback From EMA on Potential Pruritus Therapy
Tharimmune Shares Climb on Positive Feedback From EMA on Potential Pruritus Therapy
Nov 3, 2024
11:06 AM EDT, 10/30/2024 (MT Newswires) -- Tharimmune ( THAR ) shares climbed by more than 130% in recent Wednesday trading after the company said it received positive feedback from the European Medicines Agency about TH104, its candidate to treat moderate-to-severe pruritus in primary biliary cholangitis, or PBC. The feedback came in a Scientific Advice meeting, the company said, where...
Copyright 2023-2026 - www.financetom.com All Rights Reserved